Dupilumab in the Treatment of Refractory Prurigo Nodularis:Three Case Reports
Prurigo nodularis(PN)is a chronic inflammatory skin disease with nodules on the trunk and limbs accompanied by severe itching,which is more common in female patients,and the nodules are more common in both lower limbs,and its pathogenesis is still unclear,mainly involving type 2 inflammatory reaction.Dupilumab injection is a fully human monoclonal antibody(IgG4 type)targeting the interleukin-4 receptor subunit α(IL-4R-α),which can selectively inhibit IL-4/IL-13 signaling,thereby inhibiting type 2 inflammatory response.The three PN patients reported in this article achieved significant efficacy after treatment with Dupriyu combined.